A Phase 1/2 interventional study of UCART22 and CLLS52 in B-cell Acute Lymphoblastic Leukemia, sponsored by Cellectis S.A.. Active, not recruiting at 20 sites in 2 countries. Open to participants aged 12 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Cellectis S.A. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 725 studies in Burkitt Lymphoma with a site in United States — 70 open to participants now, 118 under way, 10 of them phase 3. Burkitt Lymphoma · United States.
Among the 725 studies in Burkitt Lymphoma with a site in United States, this one is the 242nd largest by enrollment of the 594 interventional ones that give a count, is one of 20 that started in 2019, is one of 83 in phase 1/2, reaches primary completion later than 29 of the 117 other live ones, and was the 634th registered.
978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.
Browse Burkitt Lymphoma studies →70 of the 725 studies in Burkitt Lymphoma with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Sunil G. Iyer · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
AIDS Malignancy Consortium · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.
This study: 12 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
725 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 341 · Phase 2 323 · Phase 3 51 · Phase 4 1
First in 1988; this study’s year is marked. 20 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is above the median of 36 across 767 interventional studies indexed under Burkitt Lymphoma.
Median enrollment 37 across the 594 interventional studies, 94 across the 40 observational. Of the 560 that completed or were terminated, 172 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 725 have an industry lead sponsor. The 10 most frequent:
Cellectis S.A. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Cellectis S.A. has 1 study filed under Burkitt Lymphoma — fewer than ten, so there is no comparison to draw.
38 of the studies in Burkitt Lymphoma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03914625Phase 3National Cancer Institute (NCI)A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | 2027-09-30 |
| NCT03150693Phase 3Alliance for Clinical Trials in OncologyInotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | 2027-11-01 |
| NCT02393157New York Medical CollegeObinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | 2026-12 |
| NCT06131801Children's Hospital Medical Center, CincinnatiPharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | 2026-12-01 |
| NCT02981628Children's Oncology GroupInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | 2026-12-31 |
Add all 38 to your calendar (.ics) → With an account.
Among the 725 studies in Burkitt Lymphoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to determine the optimal dose of CLLS52 as part of the FCA LD regimen followed by the Recommended Phase 2 Dose (RP2D) of UCART22 and evaluate the safety and efficacy of UCART22.
The criteria were revised on the registry on Nov 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort A:
- At least 70% of B-ALL blast cells must express CD22 by flow cytometry performed as per standard practice
Cohort B:
- Less than 70% of B-ALL blast cells must express CD22 by flow cytometry performed as per standard practice
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1 Dose Escalation: Several tested doses of UCART22 until the Maximum Tolerated Dose (MTD) is identified and establish RP2D. Phase 2 Part 1 Dose Optimization: Two doses of CLLS52 followed by RP2D of UCART22. Phase 2 Part 2 Dose Expansion: Optimal dose of CLLS52 followed by RP2D of UCART22.
Biological: UCART22 · Biological: CLLS52
Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
A monoclonal antibody that recognizes a CD52 antigen
Also known as: Alemtuzumab
Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) throughout the study in relation to UCART22 and/or lymphodepletion
Time frame: 24 months
Percentage of participants achieving a complete response (CR) or CR with incomplete hematologic recovery (CRi) according to the Response Criteria for acute lymphoblastic leukemia (ALL) assessed by independent response review committee
Time frame: Within 3 months at Day 28, Day 56, Day 84
Duration of Response
Time frame: From the date of the initial response to the date of disease progression or death from any cause, whichever occurs first, assessed up to 24 months4
Progression Free Survival
Time frame: From the first day of trial treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to 24 months
Overall Survival
Time frame: From the first day of trial treatment to the date of death from any cause, assessed up to 24 months
Pharmacokinetic (PK) profile/exposure levels of CLLS52 (Alemtuzumab) used during lymphodepletion
Time frame: Lymphodepletion to Day 56
Number of participants who were transplant ineligible at trial start that transition to transplant eligible as assessed by the investigator
Time frame: UCART22 infusion to Day 84
Number of participants achieving minimal residual disease (MRD) negativity
Time frame: Day 28, Day 42, Day 56, Day 84
Overall Response Rate (ORR)
ORR is defined as number of participants who have achieved CR, CRi, complete response with partial hematologic recovery (CRh), and Morphologic Leukemia-Free State (MLFS).
Time frame: At 3 months (Day 28, Day 42, Day 56, Day 84) as defined by National Comprehensive Cancer Network (NCCN) guidelines
Molecular MRD-negative event free survival (mEFS) rate
Time frame: At 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months
Changes over time on quality of life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (adults)
EORTC QLQ-C30, a cancer-specific tool that assesses global health status, functional scales, and symptom burden. The questionnaire provides functional scores (physical, role, cognitive, emotional, and social), symptom scores (fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss, constipation, diarrhoea, and financial difficulties), and a global quality of life/health status score. Patients provide their responses on a 4-category rating scale for most of the items (not at all, a little, quite a bit, and very much), and on a 7-point numeric rating scale for the global items. Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global scale, higher scores represent better health-related quality of life (HRQoL); whereas for the symptom scales lower scores represent better HRQOL.
Time frame: 24 months
Changes over time on quality of life using Pediatric Quality of Life Inventory (PedsQL) 4.0 (12-17 years)
PedsQL 4.0 is a validated tool used to assess health-related quality of life in children and adolescents aged 12 to 17 years (for subjects aged 12 years the PedsQL-Child will be used, for participants aged 13-17 years the PedsQL-Teen will be used). It evaluates four key domains: physical functioning, emotional well-being, social interactions, and school performance. It includes 23 items, each item is rated on a 5-point scale, with scores ranging from 0 to 100.
Time frame: Screening to 24 months
Changes over time on quality of life using EuroQol 5-Dimension five-level (EQ-5D-5L)
EQ-5D-5L, a self-administered, generic preference-based measure that enables health utility estimation for economic evaluation. The EQ-5D-5L includes single items such as mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Patients provide their response to each item using a 5-category rating scale (no problems, slight problems, moderate problems, severe problems, and extreme problems). Patient responses to the items are used to derive utility values for the calculation of Quality-Adjusted Life-Years in economic modelling in health technology assessment. The visual analog scale (VAS) item on the EQ-5D-5L asks patients to rate how good or bad their health is today. It is a vertical thermometer with the anchors "best imaginable health" at 100 and the "worst imaginable health" at 0.
Time frame: 24 months
Quantitation of T, B, and natural killer (NK) cells and total lymphocytes in peripheral blood (PB) pre- and post-CLLS52 administration
Time frame: UCART22 infusion to Day 84
Monitoring of anti-alemtuzumab (CLLS52) antibodies in serum pre- and post-administration of CLLS52
Time frame: Screening to Day 84
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2019 to primary completion in Sep 2026, 83 months.
Of 50 phase 1/2 interventional studies under Burkitt Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 114. This study's 83 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jun 2026 → Sep 2026 and completion Jun 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cellectis S.A.